The success of this combinatorial setting was proposed to be caused by a GVAX-induced expansion of mesothelin-specific CD8+ T cells within the tumor microenvironment, thereby enhancing the efficacy of the anti-CTLA-4 antibody treatment. This evidence concerns the gene CD8A and neoplasm.